

OFFICIAL

PTO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

To: Customer Service Center  
Fax Number: (703) 872-9306

RECEIVED  
CENTRAL FAX CENTER

MAR 09 2004

Attn: Examiner Charanjit Aulakh Group Art Unit: 1625

From: Brian L. Buckwalter  
Roche Palo Alto LLC,  
3431 Hillview Ave., Palo Alto, CA  
Return Fax No.: 650/ 855-5322

Total Pages: 11**Certificate of Transmission under 37 CFR 1.8**

I hereby certify that the correspondence cited below is being facsimile transmitted to the Patent and Trademark Office on March 9, 2004.

  
Chris Myers

[Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.]

**Documents Attached:**

For: S/N 10/608,604, filed June 27, 2003, Docket No. R0125C-CON  
inventors Ann Marie Madera, et al.

1. Amendment and Response, 8 pages
2. Terminal Disclaimer
3. Fee Transmittal

Doc 12396]

**FEE TRANSMITTAL  
for FY 2004**

Effective: 01/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27**TOTAL AMOUNT OF PAYMENT (\$)** 110.00**Complete If Known**

Application Number	10/608,604
Filing Date	June 27, 2003
First Named Inventor	Madera, Ann Marie
Examiner Name	Aulakh, Charanjit
Art Unit	1625
Attorney Docket No.	R0125C-CON

**METHOD OF PAYMENT (check all that apply)**☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None☒ Deposit Account:

Deposit Account Number 18-1700

Deposit Account Name Roche Palo Alto LLC  
3431 Hillview Avenue  
Palo Alto, CA 94304

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments  
☒ Charge any additional fee(s)  
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770			Utility filing fee	
1002	330			Design filing fee	
1003	520			Plant filing fee	
1004	750			Reissue filing fee	
1005	180			Provisional filing fee	

**SUBTOTAL (1)**

(\$ 0)

**2. EXTRA CLAIM FEES**

		Extra Claims	Fee from below	Fee Paid
Total Claims	-20 **	=	18	= 0
Independent Claims	-3 **	=	86	= 0
Multiple Dependent		X		= 0

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18			Claims in excess of 20
1201	86			Independent claims in excess of 3
1203	280			Multiply dependent claim, if not paid
1204	84			** Reissue independent claims over original patent
1205	18			** Reissue claims in excess of 20 and over original patent

**SUBTOTAL (2)**

(\$ 0)

\*\*or number previously paid, if greater; For Reissues, see above

**FEE CALCULATION (continued)****3. ADDITIONAL FEES**

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,410	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,300	2501	650	Utility issue fee (or release)	
1602	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1450	130	1450	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17 (q)	
1808	180	1808	180	Submission of Information Disclosure Stmt	
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) **TERMINAL DISCLAIMER**

110.

\*Reduced by Basic Filing Fee Paid

**SUBTOTAL (3)**

(\$ 110.00)

**SUBMITTED BY**

Name (Print/Type)

Brian L. Burkhalter

Registration No.

46,585

Telephone

650/ 855-6995

Signature

Date

03/09/04

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Doc# #123958

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED  
CENTRAL FAX CENTER

MAR 09 2004

OFFICIAL

<b>Address to:</b> Commissioner for Patents PO Box 1450 Alexandria, VA 22313  <b>FAX to:</b> 703-872-9306	<b>First Inventor</b>	Madera, Ann Marie
	<b>Application Number</b>	10/608,604
	<b>Filing Date</b>	June 27, 2003
	<b>Group Art Unit</b>	1625
	<b>Examiner</b>	Aulakh, Charanjit
	<b>Attorney Docket No.</b>	R0125C-CONT
	<b>Title:</b>	AMINO-TETRA LIN DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS

Honorable Commissioner for Patents  
Alexandria, VA 22313-1450

Sir:

**AMENDMENT AND RESPONSE**

This Amendment responds to the Office Action dated January 16, 2004 with a shortened statutory period for response set to expire April 16, 2004. Please make the following amendment and take the accompanying remarks into consideration.

Amendments to the claims are reflected in the listing of claims on page 2 of this paper.

Remarks begin on page 8 of this paper.